BIONOTE signs supply agreement with one of the three largest distributors in US▶ Technology, performance, and marketability of BIONOTE's products highly valued... will continue to increase market shareGlobal leader in Veterinary Diagnostics and Biological Raw Materials BIONOTE Inc., announced on the 25th of April that they have signed a supply agreement with Covetrus, one of the three largest distributors in the United States, expanding their sales potential for animal diagnostics in the US market.Covetrus is one of the largest distributors of animal pharmaceuticals and diagnostic products in the world with revenue of over 4 billion USD, as of 2021, supplying products to North America, Europe, and Asia. Key customer bases include animal hospitals, clinics, pharmaceutical companies, pharmacies, and pet stores. Furthermore, they also provide medical information technology solutions, financial and management software for animal hospitals.BIONOTE plans to provide their veterinary fluorescent immunoassay series, 'Vcheck F', through this supply agreement. Vcheck F is a series of products, based on immunochromatic assay technology, capable of producing accurate results through the use of highly sensitive fluorescent materials. A total of 27 markers for cardiac diseases, inflammation, etc. can be tested quantitatively, as well as qualitatively using the Vcheck F series.BIONOTE plans to expand their presence in the market and increase sales of their various products, through cooperation with Covetrus for maximizing marketing and promotional activities.Dr. Byungki Cho, CEO of BIONOTE commented that "the supply agreement between Covetrus and BIONOTE is a testament to the excellence in technology, performance and marketability of BIONOTE's products" and that "BIONOTE will continue to strive to use this opportunity to increase the market share of our products in the US market".
DISCLAIMER: This news article is a direct translation of the original Korean article from Medipana News. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BIONOTE Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.BIONOTE announced on the 11th that they are in the process of expanding further into the global market through their Point of Care Molecular Diagnostic Analyzer, 'Vcheck M10' ("M10").M10 is an automatic analyzer that can perform both nucleic acid extraction and PCR, which previously needed to be performed separately using two different machines. The test procedure is simple enough for any veterinarians to perform on-site at the animal hospitals without separate prior training. The user can receive accurate PCR results through the M10 within an hour and removes the need to send samples to specialized labs to receive results, which can take up to 3 days.Furthermore, depending on the user's needs, they are able to customize how many channels they would like to use, up to a maximum of 8, making the M10 suitable for small hospitals, large hospitals and even labs.A BIONOTE Spokesperson commented that "The 'Canine Vector 8 Panel' recently released for the M10, has been received extremely well overseas with exponentially increasing sales numbers." and that "New sales have been recorded in countries such as Australia, Hong Kong and Mexico, with multiple European Countries in line to join the list soon as well."In addition, BIONOTE is aiming to develop and launch its 'Vcheck M Diarrhea 8 Panel' within the year, while also moving forward with international clinical evaluations in order to prove the excellence of their technology. Beyond that, they are also planning to expand into the livestock animal market through developing new tests for the M10 and expanding their catalog.Dr. Byung Ki Cho, CEO of BIONOTE, stated "It is our goal to rapidly increase our global market presence and grab hold of the veterinary POC PCR market by 2025 through our various test items" and that "Along with our new POC clinical chemistry analyzer 'Vcheck C', we will be able to lead the global market in providing total diagnostic solutions."Link to original article: https://www.medipana.com/article/view.php?news_idx=310544&sch_cate=F
Bionote, a leading veterinary diagnostic company based in Korea, is introducing two new biomarkers, eProgesterone and eSAA, as a part of the Vcheck series. Vcheck eProgesterone is an in vitro diagnostic test kit for the quantitative measurement of progesterone concentration in Equine serum and plasma. This test kit precisely quantifies the degree of elevation in progesterone levels in horses. Progesterone plays a crucial role in the maintenance of pregnancy until 120 days of gestation when the placenta becomes the main source. In addition, measuring progesterone helps find out mare’s reproductive cycle and plan most effectively. Vcheck eProgesterone assay allows you to quickly analyze Equine progesterone in the field, evaluate corpus callosum in the early stages of pregnancy, and monitor progesterone during pregnancy. Vcheck eProgesterone: This one-step test procedure is easy to follow and provides fast results within 15 minutes using serum and plasma samples from horses. Vcheck Equine SAA is an in vitro diagnostic test kit for the quantitative measurement of SAA concentration in Equine serum and plasma. This test kit precisely quantifies the degree of elevation in SAA levels in horses. SAA concentration increases in response to several clinical conditions in horses, such as sepsis, viral infections, arthritis, gastrointestinal and reproductive disease. Also, its measurement is useful for monitoring the response to treatment. Vcheck Equine SAA assay allows early detection of the presence of inflammation, monitors the post-operative effects and recovery, and serial monitoring of the response to treatment. Vcheck Equine SAA: This one-step test procedure is easy to follow and provides fast results within 5 minutes using serum and plasma samples from horses. Bionote will also be introducing Vcheck Foal IgG within the first half of 2023. If you are interested in Vcheck eProgesterone and/or Vcheck Equine SAA, please contact your local distributor or mail to [bionote@bionote.co.kr].